Home | Welcome to Contract Pharma   
Last Updated Friday, May 29 2015

Print RSS Feed

Search Results for 'APIs'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published May 22, 2015
To provide aseptic and low bioburden clean room dispensing of bulk materials Read More »
Published May 12, 2015
To bolster clinical and commercial bulk drug production and fill/finish for gene therapies Read More »
Published May 11, 2015
The acquired business produces active pharmaceutical ingredients and intermediate products Read More »
Published May 8, 2015
A large pharmaceutical company wanted to develop a bilayer tablet, each layer having different release profiles. One of the layers was low dose and moisture sensitive. There were also layer lamination issues during formulation development and in stor… Read More »
Published May 5, 2015
Contract revenue up 47% in the quarter Read More »
Published April 14, 2015
Will partner to develop new compounds Read More »
Published April 6, 2015
Opens a 1600L/1000L reactor stream, increases throughput for 400L reactors Read More »
Published April 6, 2015
Activities will be transitioned to other facilities, affecting approx. 62 positions Read More »
Published March 30, 2015
Will install a new Class 100,000 suite at its North East England facility Read More »
Laurus Synthesis Launches US Operations
Published March 20, 2015
Opens facility in Woburn, MA Read More »
Published March 11, 2015
New site will offer fully integrated formulation development services Read More »
Published March 11, 2015
High containment site is in Edinburgh, UK and part of the Macfarlan Smith division Read More »
Published March 4, 2015
Expands API development and manufacturing capabilities Read More »
Published February 27, 2015
Will offer production of API using microbial expression systems Read More »
Published February 17, 2015
To provide custom biomanufacturing for commercial production Read More »
Published February 3, 2015
Expands custom chemical and biochemical manufacturing portfolio Read More »
Pharmaceutical Fine Chemicals…Quo Vadit?
By Dr. Enrico T. Polastro , Arthur D. Little
Published January 29, 2015
Captive and merchant demand estimated at $80 billion and growing 4-5% per annum. Read More »
Published January 28, 2015
To manufacture Amotosalen API for Cerus Read More »
Published January 19, 2015
Will support development and manufacture of drug candidates for neurological disorders Read More »
Published December 15, 2014
Broadens access to key biotech hubs Read More »
Published December 10, 2014
Werum's PAS-X V3.1.5 covers areas of API manufacturing and product warehouse Read More »
Published December 4, 2014
Expands sterile filling segment Read More »
Published December 1, 2014
Attributes growth to rapidly developing biopharma industry and increase in CMOs globally Read More »
Published November 21, 2014
Expands capacity for immunology and oncology pipelines Read More »
Published November 17, 2014
Warburg Pincus invests $92mn in the Indian maker of APIs. Read More »
Published October 21, 2014
Expands drug development and bioavailability capabilities Read More »
Published October 15, 2014
Increasing GMP issues may threaten patient safety unless QbD adoption grows Read More »
Published October 13, 2014
Will offer newly developed galenic forms Read More »
Published October 2, 2014
Aims to develop scalable and cost-effective process for a targeted API Read More »
Published September 4, 2014
Complies with the quality GMP & GDP standards Read More »
Published August 20, 2014
Expands geographic scale, manufacturing and lyophilization capabilities Read More »
Published August 18, 2014
To manufacture API for branded commercial drug Read More »
Published August 5, 2014
Ireland facility gains pre-approval Read More »
Published July 22, 2014
Will support a portfolio of drug substance campaigns Read More »
Published July 22, 2014
Will produce NME for U.S. market Read More »
Published July 21, 2014
Phase IIa trial scheduled for 2014 Read More »
Published June 23, 2014
Expands GMP manufacturing services for APIs Read More »
Published May 20, 2014
Secures additional manufacturing capacity for Patiromer Read More »
Published May 13, 2014
Provided process development and production of Neuronascent’s lead candidate NNI-362 Read More »
Published May 1, 2014
EDQM certifies Dimethyl Sulfoxide suitability Read More »
Published April 9, 2014
Aims to support long-term growth efforts Read More »
Published April 8, 2014
To provide APIC with additional capacity for APIs and intermediates Read More »
By Kristin Brooks
Published March 24, 2014
Expands custom API products and services Read More »
By Kristin Brooks
Published March 11, 2014
Aims to sell generic Nexium in the U.S., despite regulatory restrictions Read More »
By Gil Roth
Published February 6, 2014
Generic exclusivity boosts 4Q revenues Read More »
By Gil Roth
Published February 5, 2014
First-year goals met Read More »
By Andrew Badrot, CMS Pharma
Published January 30, 2014
DSM & Patheon unlock value through a creative merger Read More »
By Kristin Brooks
Published January 29, 2014
To produce a new class of APIs called viral vectors Read More »
By Kristin Brooks
Published January 27, 2014
Demonstrates proficiency in the safe handling of potent APIs and compounds Read More »
Risk Mitigation Through Polymorphic Screening
By Karin Liltorp, Soren Lund Kristensen and Thomas Andresen, Particle Analytical
Published January 22, 2014
Why, When & How Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On